Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Competitive Landscape of the Clinical Trials Market, Including Company Strategies, Sustainability Benchmarking, Key Player Developments, and Revenue...
-
Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Real World Data (RWD) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The real-world data (RWD) market is on a rapid...
-
Dublin, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The "Writing Clinical Research with Integrity Training Course (Apr 20, 2026)" training has been added to ResearchAndMarkets.com's offering. This course...
-
MicrobiotiX and WAFCIRC sign MoU and Research Collaboration Agreement in Ghana, launching clinical research to evaluate phage therapy for AMR infections.
-
Dublin, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The "Global Biotech Handbook" directory has been added to ResearchAndMarkets.com's offering. The fully revised and expanded Global Biotech Handbook...
-
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,...
-
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,...
-
The acquisition expands scalable trial operations across real-world care settings
-
Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3 Dans l’étude de phase 3 LEAP2MONO, le venglustat, administré...
-
Sanofi's investigational drug venglustat improved the neurologic symptoms of type 3 Gaucher disease, for which there are currently no approved therapies.